PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 1, 2024Journal of Inflammation Research7 citations

Assessment of Immune Status in Patients with Mismatch Repair Deficiency Endometrial Cancer

View Full Paper
JMJincheng MaQingdao UniversityJLJiansong LinFujian Medical UniversityXLXite LinFujian Medical University

Key Points

Key points are not available for this paper at this time.

Abstract

Objective: This study introduced a novel subtype classification method for endometrial cancer (EC) with mismatch repair deficiency (MMRd) by employing immune status and prognosis as the foundational criteria.The goal was to enhance treatment guidance through precise subtype delineation.Methods: Study Cohort: This study encompassed a cohort of 119 patients diagnosed with MMRd-EC between 2015 and 2022.Analyses using t-tests and Mann-Whitney U-tests were performed to assess prognostic markers and peripheral blood immune cell profiles in patients with MutS deficiency (MutS-d) versus those with MutL deficiency (MutL-d).Logistic regression analysis was used to identify independent risk factors.Bioinformatics Analysis: An online database was used to assess the prognostic implications, immune cell infiltration, and immune checkpoint involvement associated with the deficiency of MutS versus MutL in EC.Results: Patients with MutL-d exhibited heightened risk factors, including elevated cancer grade and increased myometrial invasion, leading to poorer prognosis and shorter overall survival and progression-free survival.Regarding systemic immune status, patients with MutL-d demonstrated decreased peripheral blood lymphocyte percentage, lymphocyte count, and CD8+ T cell percentage.For local immunity, the infiltration of natural killer cells, CD8+ T cells, and cytotoxic T lymphocytes in the tumor tissue was reduced in patients with MutL-d.Additionally, patients with MutL-d exhibited lower expression of immune checkpoint markers.The composition of immune subtypes and survival outcomes also indicate that patients with MutL-d have a poorer immune status and prognosis than the patients with MutS-d. Conclusion:Patients with MMRd-EC can be subclassified according to MutS or MutL deficiency.Patients with MutS-d exhibited better immune status, prognosis, and immunotherapy benefits than those with MutL-d.These results can help guide patients to a more precise treatment.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ma et al. (2024) studied this question.

synapsesocial.com/papers/68e70efbb6db643587688846https://doi.org/10.2147/jir.s453337
Ask AI
Helpful
Bookmark
Share
View Full Paper